This Year's Highlights

• September, 2006: InViragen entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention. The licensed technology is applicable to vaccines against viral diseases such as dengue fever and West Nile.
• September, 2006: InViragen received a four year, $2.8 million dollar grant from the National Institutes of Health to partially support preclinical development of a safe and effective dengue vaccine.
• October, 2006: InViragen entered into an agreement with Shantha Biotechnics (Hyderabad, India) for the manufacture of InViragen?s proprietary dengue vaccine for human clinical trials.

Anticipated Highlights

• InViragen will soon announce receipt of an Advanced Technology grant from the National Institutes of Health for the engineering and testing of a novel avian influenza vaccine in collaboration with leading scientists at the University of Wisconsin.
• InViragen will soon announce completion of a strategic agreement with the Pediatric Dengue Vaccine Initiative (PDVI), a public private partnership devoted to accelerating the introduction of dengue vaccines in the developing world.

Corporate Mission

InViragen, LLC is focused on developing vaccines for new emerging markets worldwide. Over 15 million people die of infectious diseases globally. 5 million of those deaths are children. Vaccines remain the most cost effective means of preventing those deaths.

The vaccine industry is rapidly changing. The middle class in developing countries such as India, China, Mexico and Brazil are buying vaccines at higher prices from their physicians and clinics. Non-profit institutions, such as the Bill and Melinda Gates Foundation, are creating novel public-private partnerships to reduce the costs of vaccine development and are creating mechanisms to ensure demand at higher prices. Due to flu vaccine shortages and emerging disease threats (such as SARS, West Nile and avian influenza), there is increased government awareness of the value of vaccines that has lead to increased funding for vaccine development, initiatives to assure demand, and legislation to limit liability. Finally, the looming threat of using infectious diseases as bioweapons has increased interest in vaccines for diseases that are no longer affect public health, such as smallpox, anthrax and plague.

InViragen is positioned to take advantage of these changes in the vaccine marketplace. InViragen?s lead product is a vaccine for dengue fever. The dengue viruses are endemic to Asia, Central and South America, the Caribbean, the Pacific Islands, and parts of Africa and Australia, threatening one third of the world?s population. The company is also pursuing a promising vaccine technology developed at the CDC for West Nile disease. Since its emergence in New York in 1999, West Nile virus has caused over 16,000 documented human cases of disease and over 600 deaths in the United States. InViragen also has received funding to develop novel safe and effective vaccines to protect against potential bio-terrorism agents such as smallpox and plague.